Antithrombin Market, By Type (Thrombolytic Drugs, Anticoagulant, Antiplatelet and Others), By Application (Therapeutics, Research & Development, Diagnostics, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2030

Antithrombin Market size accounted for USD 577.2 Million in 2020 and is projected to reach USD 849.87 Million by 2030 and is anticipated to register a CAGR of 4.3%.

Antithrombin is the substance present in the blood. Antithrombin helps limit the blood's ability to coagulate. Antithrombin is the plasma protein. Antithrombin acts as an important regulator in blood coagulation. Antithrombin is an important physiological anticoagulant that inactivates multiple coagulation factors and thrombin. During DIC (disseminated vascular coagulation), antithrombin strongly inhibits the over-activation of the coagulation system. Antithrombin is approved by the FDA as an anticoagulant before or during surgery for the prevention of clots. Antithrombin drugs are low molecular weight heparin (LMWH), unfractionated heparin (UFH), bivalirudin, and fondaparinux.

Mutations in the SERPINC1 gene cause hereditary antithrombin deficiency. Clot-busting drugs are called thrombolytic drugs which break up and dissolve blood clots. Streptase (streptokinase), Eminase (anistreplase), and Retavase (reteplase) are examples of thrombolytic drugs. Tissue plasminogen activator is the common drug used for thrombolytic therapy. Anticoagulants help in preventing blood clots. Dabigatran (Pradaxa), edoxaban (Lixiana), rivaroxaban (Xarelto) and apixaban (Eliquis) are the examples of anticoagulants. When there is a disruption in the flow of blood anticoagulants are used. The rise in surgeries has given rise in the use of Antithrombin thus resulting in the growth of the market.

Rise in surgical procedures

Rise in surgical procedure is one of the leading factors for the global antithrombin market growth. Rise in prevalence of disease has led to increase in surgical procedures. DTo ease the paiun and for treatment of diseases the surgical procedures are performed. Increase in chronic diseases like heart, kidney disease has given rise in surgeries. Purpose of surgery is to improve the physical appearance, transplant tissue or whole organs, repairing diseased tissue or organs, to reposition the structure to its normal position. Antithrombin is used before, after and during the surgical procedures which helps in preventing the blood clots. For instance, in 2002, the Antithrombin III concentrate was used to treat the heparin resistance in patients who were undergoing the cardiac surgery. Treatment with Antithrombin III concentrate was resulted in giving potentiality of heparin effect to meet the activated clotting time and thus allowed for cardiac surgery. However, the growth in surgical procedures has boosts the demand for antithrombin market.

Rise in antithrombin deficiency and demand for antithrombin

Rise in antithrombin deficiency and demand for antithrombin has become the major factor in growth of antithrombin market. Deficiencies of anticoagulants and antithrombin gives rise to high risk of thrombophilias. Maintaining adequate levels of antithrombin is very important to prevent high risk thrombophilias. Antithrombin also has excellent anti-inflammatory properties and great affinity for thrombin. Due to its remarkable properties antithrombin are high in demand. Antithrombin is complex molecule with biological properties.  For instance, in 2013, the clinical use and Italian demand for antithrombin has increased due to its remarkable properties. For instance, in 2009, use of antithrombin concentrates prothrombin complex concentrates were recommended therapeutically in primary and acquired antithrombin deficiency.

Restrains:

However, risk of blood borne diseases may somewhat restrain the growth of the target market.

The antithrombin market is segmented based on type, application, and region.

On the basis of type, the antithrombin market is segmented into Thrombolytic Drugs, Anticoagulant, Antiplatelet and others. On the basis of application, the target market is classified into Therapeutics, Research & Development, Diagnostics, and others.

Regional Insights:

In the region, the antithrombin market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period, owing to the growing population, especially in countries such as India and China, and technological advancements. Moreover, the rising presence of industrial corridors and increased incidence of cardiac disease is anticipated to increase demand for antithrombin in the region.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented the global antithrombin market report based on type, application, and region:

Antithrombin Market, By Type:

• Thrombolytic Drugs
• Anticoagulant
• Antiplatelet
• Others

Antithrombin Market, By Application:

• Therapeutics
• Research & Development
• Diagnostics
• Others

Antithrombin Market, By Region:

• North America
  • Middle East & Africa
    • • GCC
      • Israel
      • South Africa
      • Rest of Middle East & Africa
  • Latin America
    • • Brazil
      • Mexico
      • Rest of Latin America
  • Asia Pacific
    • • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
  • Europe
    • • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • • U.S.
    • Canada

The key players operating the antithrombin market includes, Takeda Pharmaceuticals, Siemens AG, Axis-Shield Plc., Grifols, CSL Limited, Thermo Fisher Scientific, Octapharma AG, Lee Biosolutions Inc., Shire Plc., LFB USA, Scripps Laboratories Inc., Kedrion S.p.A., Novartis International AG, Bristol-Myers Squibb Company, Merck & Co, and others. Prominent players operating in the target market are focusing on the strategic partnerships as well as launching of the products in order to gain competitive edge in the target market. For instance, in 2022, Grifols signs the global collaboration agreement with the Endpoint Health to develop and commercialize Antithrombin III for treatment of Sepsis and blood clotting disorder.

• Grifols
• Takeda Pharmaceuticals
• Siemens AG
• Axis-Shield Plc.
• CSL Limited
• Thermo Fisher Scientific
• Octapharma AG
• Lee Biosolutions Inc.
• Shire Plc.
• LFB USA
• Scripps Laboratories Inc.
• Kedrion S.p.A.
• Novartis International AG
• Bristol-Myers Squibb Company
• Merck & Co.